U.S. Life Sciences Stock News

Darden Restaurants reported past fiscal second-quarter 2026 results showing sales of US$3,102.1 million and net income of US$237.2 million, alongside updated full-year 2026 guidance calling for total sales growth of 8.5% to 9.3% and same-restaurant sales growth of 3.5% to 4.3%. Despite elevated beef costs, Darden delivered same-restaurant sales gains across Olive Garden and LongHorn Steakhouse, leaned on promotions like Never Ending Pasta Bowl, opened more new restaurants than planned, and...

Prosperity Bancshares (PB) has been quietly grinding higher, with the stock up about 5% over the past month and 9% in the past 3 months, even as year-to-date returns remain slightly negative. See our latest analysis for Prosperity Bancshares. That recent 1 month share price return of around 5% sits against a slightly negative year to date share price performance. At the same time, the 5 year total shareholder return of just over 21% suggests momentum is gradually rebuilding rather than...

Earlier this month, Williams-Sonoma’s Board of Directors declared a quarterly cash dividend of US$0.66 per share, payable on February 20, 2026 to shareholders of record as of January 16, 2026. This latest dividend declaration highlights the retailer’s ongoing use of cash returns alongside buybacks to reward shareholders while it continues investing in its business. We’ll now explore how this renewed dividend commitment fits into Williams-Sonoma’s broader investment narrative built around...

WhiteFiber’s Enovum Data Centers subsidiary previously signed a 10-year colocation agreement with Nscale Global Holdings for 40 megawatts of IT load at the NC-1 AI data center campus in Madison, North Carolina, carrying an estimated US$865 million in contracted revenue. The deal makes Nscale the anchor tenant at NC-1, giving WhiteFiber clearer long-term revenue visibility and support for potential campus expansion tailored to advanced AI workloads. Next, we’ll explore how anchoring NC-1 with...

Intel (INTC) has quietly put together a solid run, with the stock up roughly 7% over the past month and almost 90% over the past year, outpacing much of the semiconductor space. See our latest analysis for Intel. At a share price of $36.82, Intel’s 30 day share price return of 6.7% and sharply stronger 1 year total shareholder return of 88.6% suggest momentum is still building as investors reassess its turnaround and foundry ambitions. If you are watching Intel’s revival and wondering what...

SFL (NYSE:SFL) just reshuffled a key slice of its tanker fleet, selling two 2015-built Suezmax vessels and ending charters on two newer ships to free up cash for younger, more efficient tonnage. See our latest analysis for SFL. The move comes after a choppy year for SFL, with a 1 year to date share price return of negative 25.41 percent and a softer 1 year total shareholder return of negative 10.62 percent. The 5 year total shareholder return of 99.50 percent still points to solid long term...

PennyMac Financial Services (PFSI) just caught a tailwind, with shares climbing after a fresh Buy call from Jefferies and a more optimistic stance from Keefe, Bruyette and Woods, both leaning into its earnings momentum. See our latest analysis for PennyMac Financial Services. That bullish call is landing on an already strong tape, with the share price at $134.62 after a 34.84% year to date share price return and a hefty 145.34% three year total shareholder return. This shows that momentum is...

In November 2025, Copa Holdings reported a 10% year-over-year increase in available seat miles to 2,777.6 million and a 10.2% rise in revenue passenger miles to 2,394.7 million, lifting its system load factor slightly to 86.2%. This combination of capacity growth and steady high load factors highlights how Copa is filling additional seats without diluting demand, reinforcing confidence in its regional network strength. Next, we’ll examine how November’s 10% capacity increase and firm 86.2%...

MiMedx Group (MDXG) just added fresh peer reviewed backing for its placental allograft products, with a new Journal of Inflammation study underscoring their immunomodulatory role in complex wound healing and longer term competitive positioning. See our latest analysis for MiMedx Group. Even with this new clinical validation, MiMedx Group’s $7.05 share price sits well below its highs, with a year-to-date share price return of negative 24.03 percent and a powerful three-year total shareholder...

On December 12, 2025, Tyson Foods entered a new Loan Agreement with CoBank, replacing its prior term loan with a senior unsecured revolving credit facility of up to $750 million that matures in three years and includes options to convert borrowings into longer-term tranches. This shift from a fixed term loan to a flexible revolving structure, with the ability to term out debt later, gives Tyson Foods more control over liquidity management, funding costs, and timing of capital needs. We’ll...

In recent days, several major banks including JPMorgan, Barclays, and Keefe, Bruyette & Woods reaffirmed positive analyst ratings on Webster Financial, while Seaport Global reiterated a more cautious Hold stance. This cluster of bullish opinions alongside insider share sales highlights a tension between external optimism about Webster’s prospects and internal portfolio decisions by company executives. We’ll now examine how this wave of upbeat analyst sentiment, especially around regional...

Corcept Therapeutics (CORT) has quietly turned into a strong performer this year, with the stock up about 68% year to date and roughly 63% over the past year, far outpacing the broader market. See our latest analysis for Corcept Therapeutics. The recent 1 month share price return of 8.37% and the latest close at $83.76 suggest investors are steadily repricing Corcept as growth expectations and perceived pipeline risks shift, building on a powerful multi year total shareholder return. If...

Zebra Technologies (ZBRA) has had a choppy run lately, with the stock sliding over the past 3 months even as revenue and net income keep growing. This sets up an interesting valuation debate. See our latest analysis for Zebra Technologies. Zooming out, the stock’s recent 7 day and 90 day share price declines sit against a much steeper year to date slide. At the same time, the 3 year total shareholder return is only slightly positive, suggesting momentum has been fading even as fundamentals...

Balchem (BCPC) just rolled out a 10.3% dividend increase alongside a fresh buyback authorization for up to 4 million shares, a one two signal that management is leaning into shareholder returns. See our latest analysis for Balchem. Those moves land after a fairly muted stretch for the stock, with the share price down modestly year to date even as the five year total shareholder return of 40% shows longer term compounding still at work. If this kind of shareholder friendly story appeals to...

In recent months, analysts at Wells Fargo, Citi, Mizuho, UBS, and others have updated their views on RPM International, with most maintaining positive ratings even as some grew more cautious and insiders increased share sales. This combination of broadly supportive analyst sentiment and rising insider selling offers investors a contrasting read on how external and internal stakeholders view RPM’s prospects. We’ll now explore how this mix of largely positive analyst opinions and heightened...

Piper Sandler analyst Matthew Clark recently maintained a Sell rating on Cathay General Bancorp, as corporate insiders including Vice Chairman Anthony Tang have been increasing share sales amid ongoing operational headwinds. Behind these developments, Cathay General Bancorp has faced a 1.7% decline in annual sales and a 7.5% annual drop in earnings per share over the past two years, pointing to persistent profitability challenges. With analysts turning more cautious and insiders increasing...

KB Home (KBH) just delivered one of those mixed quarters that gets everyone talking, beating expectations on earnings and revenue while simultaneously dialing back its outlook as affordability pressures and a thinner backlog cloud 2026. See our latest analysis for KB Home. The market has quickly repriced that cautious 2026 guidance, with an 8.5% one day share price decline and double digit year to date share price retreat. However, three year total shareholder return remains very strong and...

Watsco (WSO) just delivered a softer quarter, with revenue slipping about 4% year over year to roughly $2.1 billion and missing Wall Street expectations, and the stock quickly reflected that disappointment. See our latest analysis for Watsco. The muted 1 day share price return of around negative 0.2%, at about $347.83, comes on top of a weak year to date share price return and a roughly negative 26% 1 year total shareholder return. This suggests momentum has been fading even after a strong...

ResMed recently received U.S. FDA clearance for its AI-enabled Smart Comfort feature, which uses de-identified sleep data to personalize CPAP comfort settings for new AirSense 11 users via the myAir app. This marks one of the earliest FDA-cleared uses of AI to individualize CPAP comfort, aiming to improve long-term adherence for millions of U.S. obstructive sleep apnea patients while easing clinicians’ setup workload. Next, we’ll explore how FDA-cleared AI personalization through Smart...

In recent days, Guardant Health and Trial Library announced a collaboration to use AI and Guardant’s precision oncology diagnostics to match more U.S. cancer patients to clinical trials, while an Italian hospital, Policlinico Gemelli, launched an in-house liquid biopsy service based on Guardant360 CDx technology for routine care and research. Together, these moves highlight how Guardant is embedding its testing and data platform directly into major care settings and trial networks,...

Earlier this month, Caliber announced it had selected StoneX as an additional institutional platform for trading and custody to support its Digital Asset Treasury strategy centered on Chainlink’s token, LINK, using StoneX Prime’s deep liquidity and institutional-grade infrastructure. This mandate reinforces StoneX’s position as a key infrastructure provider for listed companies seeking transparent, on-balance-sheet exposure to digital assets. Next, we’ll examine how StoneX’s role in...

Earlier this month, DRMTLGY announced that its clinical skincare line had launched exclusively at Ulta Beauty, rolling out across more than 1,400 stores nationwide and Ulta.com with 13 curated products highlighted through prominent in‑store displays and digital promotion. This exclusive partnership deepens Ulta Beauty’s emphasis on science‑focused, results‑oriented skincare, potentially reinforcing its appeal among ingredient‑conscious shoppers seeking medical‑grade options at more...

In recent days, Globus Medical drew renewed attention as multiple research firms reaffirmed positive views on the company, citing confidence in its musculoskeletal and enabling-technology portfolio alongside encouraging clinical trial progress. What stands out is that this cluster of upbeat analyst opinions, combined with clinical milestones, appears to be reshaping how investors assess Globus Medical’s long-term growth drivers and execution risks. Next, we’ll examine how this wave of...

SS&C Technologies Holdings (SSNC) just reported that its GlobeOp Forward Redemption Indicator slipped to roughly 2% in December, down from the prior month and last year. This hints at steadier hedge fund assets on its platform. See our latest analysis for SS&C Technologies Holdings. That backdrop of steadier hedge fund assets comes after a busy period, including SS&C presenting at the Nasdaq Investor Conference in London. It helps explain why the stock’s roughly 16% year to date share price...